Anti-inflammatory Cells in Peritoneal Cavity

Can the Peritoneal Cavity be a Source of Regulatory B Cells to Treat Auto-immune Disease?

Status

Terminated

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03189316

Enrollment

Registered

2017-06-16

Start date

2017-06-06

Completion date

2017-12-13

Last updated

2018-06-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Renal Insufficiency, Ovarian Cysts

Keywords

Peritoneal fluid, B cells, Regulatory B cells, Human

Brief summary

Some subsets of lymphocytes are able to inhibit immune response and thus, could be used to control auto-immune diseases and transplant reject. In mice, the main source of those anti-inflammatory lymphocytes is the peritoneal cavity. No data are available in human. This study aims at exploring the presence of those anti-inflammatory lymphocytes in human peritoneal cavity and at determine how to expand those cells.

Detailed description

B cells will be collected during procedures planned for patients' standard care. Peritoneal fluid and peripheral blood of patients will be collected during coelioscopy for exploration of ovarian cysts or dialysis for treatment of chronic renal insufficiency. Regulatory B cells (Breg cells) will be measured in peritoneal fluid and in peripheral blood after in vitro stimulation and assessment of intracellular interleukin-10 by flow cytometry. Proportion of Breg cells among B cells will be compared between peritoneal fluid and peripheral blood in both groups. Different protocols to induce differentiation of B cells into Breg cells will be tested and compared.

Interventions

OTHERperitoneal fluid and blood sample

Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample or Peritoneal fluid obtained from coelioscopy for exploration of ovarian cysts and blood cell

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

BASIC_SCIENCE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* woman over 18 year old undergoing exploration of ovarian cysts by coelioscopy * patient with chronic renal insufficiency undergoing peritoneal dialysis * informed consent obtained

Exclusion criteria

* pregnancy or breast-feeding * non affiliation to health care insurance * treatment with corticosteroids over 15 mg/day * treatment with rituximab

Design outcomes

Primary

Measure	Time frame	Description
relative percentage of regulatory B cells among B cells in peritoneal cavity compared to peripheral blood	up to 48 hour	Comparison of Breg cell in peritoneal cavity to Breg cell in peripheral blood B

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026